IFNG and cancer: Consistently, in a mouse model of sarcoma, the tumor glucose consumption dampened T cell mammalian target of rapamycin complex 1 (mTORC1) activity, their capacity to do glycolysis and to produce IFNγ, lowering adaptive anti-tumor activity in spite of the high antigenicity of the cancer cells (63, 64) (see Figure 2).